Medicine and Dentistry
Breast Cancer
100%
Malignant Neoplasm
23%
Trastuzumab
21%
Gamma Urogastrone
19%
Epidermal Growth Factor Receptor 2
18%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
15%
Neoplasm
14%
Recurrent Disease
13%
Clinical Trial
13%
Clinical Oncology
12%
Oncology
12%
Disease
11%
Triple Negative Breast Cancer
10%
Metastatic Breast Cancer
10%
Adjuvant Therapy
10%
Hormone Therapy
10%
Hormone Receptor
9%
Biological Marker
9%
Estrogen Receptor
8%
Overall Survival
8%
Paclitaxel
8%
Adjuvant Chemotherapy
8%
Pathologist
8%
Survivorship in Cancer Care
7%
Disease Free Survival
7%
Cancer Therapy
7%
Hazard Ratio
7%
Arm
6%
Targeted Therapy
6%
Lapatinib
6%
Clinician
6%
Systematic Review
5%
Symptom
5%
Progesterone Receptor
5%
Electrocorticography
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
60%
Chemotherapy
21%
Trastuzumab
21%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
14%
Malignant Neoplasm
14%
Gamma Urogastrone
13%
Neoplasm
13%
Paclitaxel
13%
Epidermal Growth Factor Receptor 2
12%
Metastatic Breast Cancer
11%
Disease
11%
Recurrent Disease
10%
Hormone Receptor
9%
Disease Free Survival
9%
Overall Survival
9%
Clinical Trial
9%
Lapatinib
8%
Triple Negative Breast Cancer
7%
Doxorubicin
6%
Taxane
6%
Endocrine Therapy
5%
Anthracycline
5%
Capecitabine
5%
Cyclophosphamide
5%
Biological Marker
5%
Phase II Trials
5%
Keyphrases
Breast Cancer
30%
Early Breast Cancer
16%
Trastuzumab
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Metastatic Breast Cancer
12%
Chemotherapy
9%
Endocrine Therapy
8%
Hazard Ratio
8%
Disease-free Survival
8%
Triple-negative Breast Cancer
7%
Pathological Complete Response
7%
Tumor
7%
Paclitaxel
7%
College of American Pathologists
6%
American Society of Clinical Oncology
6%
Invasive Breast Cancer
6%
Clinical Practice Guidelines
5%
Lapatinib
5%
Adjuvant Therapy
5%
HER2-positive Breast Cancer
5%
Phase II Study
5%
Overall Survival
5%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
5%
Estrogen Receptor
5%
Randomized Clinical Trial
5%
Clinical Trials
5%
Breast Cancer Treatment
5%
Hormone Receptor-positive
5%